| Victory Metals Limited (VTM) ORDINARY FULLY PAID |
Materials |
$98 |
Renowned Geoscientist Prof Collerson appointed as Director
|
30 Jul 2024 9:08AM |
$0.340 |
$0.850 |
risen by
150%
|
|
| Bhagwan Marine Limited (BWN) ORDINARY FULLY PAID |
Industrials |
$139 |
Corporate Governance Statement
|
30 Jul 2024 9:08AM |
$0.049 |
$0.505 |
risen by
930.61%
|
|
| Bhagwan Marine Limited (BWN) ORDINARY FULLY PAID |
Industrials |
$139 |
Bhagwan Marine Commences Trading on the ASX
|
30 Jul 2024 9:08AM |
$0.049 |
$0.505 |
risen by
930.61%
|
|
| Delta Lithium Limited (DLI) ORDINARY FULLY PAID |
Materials |
$122 |
Notification regarding unquoted securities - DLI
|
30 Jul 2024 9:08AM |
$0.235 |
$0.170 |
fallen by
27.66%
|
|
| Pengana International Equities Limited (PIA) ORDINARY FULLY PAID |
Financials |
$303 |
Update - Notification of buy-back - PIA
|
30 Jul 2024 9:07AM |
$1.100 |
$1.180 |
risen by
7.27%
|
|
| Zip Co Limited (ZIP) ORDINARY FULLY PAID |
Financials |
$3,779 |
4Q24 Appendix 4C Quarterly Cash Flow Report
|
30 Jul 2024 9:07AM |
$1.845 |
$2.920 |
risen by
58.27%
|
|
ZIP - Price-sensitive ASX Announcement
Full Release
Key Points
- Zip Co Limited released its 4Q24 Appendix 4C Quarterly Cash Flow Report.
- The company reported $224,002,000 in receipts from customers for the current quarter.
- Operating activities resulted in a net cash inflow of $65,206,000 in the current quarter.
- Investing activities reported minor positive cash flow primarily from the sale of receivable loans.
- Financing activities resulted in a net cash outflow of $38,643,000 including repayment of borrowings and transaction costs.
- End of the period saw a net increase in cash and equivalents by $27,808,000.
- The report highlights transactions involving various financing facilities and repayments.
- Zip Co Limited successfully completed several refinancing activities and new facility establishment during the quarter.
- Unused financing facilities available at the end of the quarter amounted to $353,112,000.
- Total cash and cash equivalents at the end of the quarter were $353,006,000.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| PainChek Ltd (PCK) ORDINARY FULLY PAID |
Health Care |
$64 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2024 9:07AM |
$0.040 |
$0.035 |
fallen by
12.50%
|
|
PCK - Price-sensitive ASX Announcement
Full Release
Key Points
- PainChek Ltd submitted its Quarterly Activities/Appendix 4C Cash Flow Report for Q4 FY22.
- The company reported a total revenue of AUD 2.2 million, reflecting year-on-year growth.
- PainChek received the CE Mark for its PainChek Infant App in the UK and Europe, broadening its market reach.
- The company secured multiple new contracts and renewals, contributing to increased revenues.
- PainChek's technology assessments were published in peer-reviewed journals, corroborating its clinical validity.
- The company has ongoing engagements with aged care facilities and healthcare providers to expand its user base.
- PainChek reported strong cash reserves, supporting its operational and expansion plans.
- The report highlights the company's strategic focus on international market expansion and product development.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| TrivarX Ltd (TRI) ORDINARY FULLY PAID |
Health Care |
$5 |
Positive Results from Phase 2 SAMDE Study
|
30 Jul 2024 9:07AM |
$0.036 |
$0.008 |
fallen by
77.78%
|
|
TRI - Price-sensitive ASX Announcement
Full Release
Key Points
- TrivarX Limited announces positive results from Phase 2 SAMDE study.
- The study analyzed 400 patients using the MEB-001 algorithm for detecting current Major Depressive Episode (cMDE).
- MEB-001 showed high performance with 87% sensitivity and 72% specificity.
- Positive Predictive Value was 35%, and Negative Predictive Value was 97%.
- MEB-001 uses EEG and ECG signals recorded during sleep for diagnosis.
- The results validate MEB-001's potential in screening for cMDE.
- There is no current screening for cMDE in sleep centers, indicating a commercial opportunity.
- The company aims for MEB-001 to be the first depression screening tool used in clinical sleep centers.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Sultan Resources Limited (SLZ) ORDINARY FULLY PAID |
Materials |
$1 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2024 9:07AM |
$0.007 |
$0.005 |
fallen by
28.57%
|
|
SLZ - Price-sensitive ASX Announcement
Full Release
Key Points
- Sultan Resources conducted RC drilling at the Calesi prospect near Kulin, WA.
- Two holes were drilled to depths of 210m and 350m respectively.
- No economically significant Au values were noted in the composite samples.
- RTX highlighted local zones within the system of significantly higher conductance.
- The Company submitted initial 5m composite samples for gold and multi-element analysis.
- Drilling into the ultramafic sequence is expected to support its fertility to host Ni-Co sulfides.
- Access to the full extent of the target area for drilling has been ongoing since early 2022.
- Sultan’s cash position as at 30 June 2024 was ~$584,000.
- The Board of Sultan Resources Ltd advises that the Annual General Meeting will be held on 21 November 2024.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Technology One Limited (TNE) ORDINARY FULLY PAID |
Information Technology |
$13,206 |
Investor Day announces TAM of $13.5B and $1B ARR by FY30
|
30 Jul 2024 9:06AM |
$19.590 |
$40.340 |
risen by
105.92%
|
|
TNE - Price-sensitive ASX Announcement
Full Release
Key Points
- Technology One Limited announced a TAM of $13.5B and $1B+ ARR by FY30.
- Continuous growth in the UK and APAC regions with plans to double in size every five years.
- Significant investments planned in research and development to support growth.
- Introduction of SaaS+ solutions to enhance customer experiences and streamline implementations.
- Strategic acquisitions to support expansion and growth targets.
- Focus on lifting profit margins to 35%+ through economies of scale and NRR of 115-120%.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| archTIS Limited (AR9) ORDINARY FULLY PAID |
Information Technology |
$59 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2024 9:06AM |
$0.077 |
$0.205 |
risen by
166.23%
|
|
AR9 - Price-sensitive ASX Announcement
Full Release
Key Points
- Strong annual revenue growth of 54% with a 58% increase in licensing revenue
- Gross margin increased to 60% with a 79% increase in gross margin dollars
- Annual operating expenses decreased by 18%
- Positive annual operating cash flow of $1.4M with record cash receipts
- Annual Recurring Revenue (ARR) surpassed $4M
- Continued growth in target markets with significant wins, including Australian Department of Defence
- Successful retention and expansion of the existing customer base leading to net annual revenue growth of 104%
- Two CyberSecurity Excellence Award wins
- New appointments including Andrew Burns as Chief Financial Officer (CFO) and Co-Secretary
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Emyria Limited (EMD) ORDINARY FULLY PAID |
Health Care |
$13 |
June 2024 Quarterly Activities Report and Appendix 4C
|
30 Jul 2024 9:06AM |
$0.044 |
$0.027 |
fallen by
38.64%
|
|
EMD - Price-sensitive ASX Announcement
Full Release
Key Points
- Emyria Limited reported strong revenue growth, with clinical billings exceeding $1 million, marking a 60% increase in mental health service-related revenues.
- The company opened a new Empax Centre dedicated to mental health treatment, including PTSD.
- Expansion efforts included securing $499,411 in non-dilutive funding from the Western Australian Government for the MDMA analogue drug development program.
- Emyria entered a research study agreement with Reach Wellness to study MDMA-assisted therapy for PTSD in first responders.
- The IMPACT-2 trial was launched to investigate the effects of methylone on PTSD symptoms.
- The company trained additional clinicians to meet growing service demands.
- Net cash used in operating activities was $1.6 million for Q4 FY24, with clinical billings collected during the quarter amounting to $1,092,087.
- Emyria received firm commitments for $2.3 million, with $1.98 million received during the quarter.
- The Empax Centre started fee-for-service activities and achieved accreditation for providing Esketamine treatments.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Strickland Metals Limited (STK) ORDINARY FULLY PAID |
Materials |
$339 |
Significant High Grade Intercept Unlocks 1.4KM Gold Trend
|
30 Jul 2024 9:06AM |
$0.088 |
$0.150 |
risen by
70.45%
|
|
STK - Price-sensitive ASX Announcement
Full Release
Key Points
- Significant high-grade intercept at Warmblood of 14.4 meters at 6.0g/t Au from 114 meters, including 7 meters at 10.6g/t Au
- Mineralisation at Warmblood remains open at depth and down-plunge
- Recent analysis shows a mineralised trend extending further 400 meters north and 1,000 meters south, totaling a 1.4-kilometer strike length
- Additional diamond drilling north of Palomino has expanded high-grade mineralisation down-plunge
- Significant drill results at Palomino include 14.9 meters at 3.9g/t Au from 222.1 meters and 19 meters at 3g/t Au from 45 meters
- High-grade results at Palomino historically considered lower-grade
- Assay turnaround times are slow due to a backlog of over 40 sample submissions
- Ongoing drilling at Horse Well Gold Camp shows inter-connected high-grade lodes with a north-northwest plunge
- Potential for substantial mineralisation at depth at Warmblood
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zelira Therapeutics Limited (ZLD) ORDINARY FULLY PAID |
Health Care |
$5 |
Appendix 4C Cash Flow Report
|
30 Jul 2024 9:05AM |
$0.630 |
$0.450 |
fallen by
28.57%
|
|
ZLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Net cash used in operating activities for the quarter was $553,000.
- Cash and cash equivalents at the end of the period were $586,000.
- Net cash from financing activities was $1,029,000.
- Total available funding at the end of the quarter was $3,834,000.
- Estimated quarters of funding available is 6.9.
- Payments to related parties for the quarter amounted to $259,000.
- Total financing facilities available at the quarter end were $7,172,000, with $3,924,000 drawn.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Waratah Minerals Limited (WTM) ORDINARY FULLY PAID |
Materials |
$64 |
High-Grade Results & Drilling Recommences at Spur Project
|
30 Jul 2024 9:05AM |
$0.315 |
$0.275 |
fallen by
12.70%
|
|
WTM - Price-sensitive ASX Announcement
Full Release
Key Points
- Results received from a further eight drill holes from the Spur gold-copper project.
- Drilling has extended shallow high-grade gold mineralisation at Spur with notable intercepts.
- A new priority epithermal gold zone confirmed at Dalcoath West.
- RC drilling has recommenced following recent high-grade intercepts at Spur.
- Further drilling results expected in late August 2024.
- The Spur Project is located 5km west of the Newmont Corporation's Cadia Valley Project.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| MRG Metals Limited (MRQ) ORDINARY FULLY PAID |
Materials |
$10 |
30 June 2024 Quarterly Activities & Cashflow Report
|
30 Jul 2024 9:05AM |
$0.004 |
$0.004 |
fallen by
12.50%
|
|
MRQ - Price-sensitive ASX Announcement
Full Release
Key Points
- Signed a Binding Joint Venture Agreement with Sinowin Lithium to develop Mozambique Corridor Sands projects.
- Continued exploration programs in Mozambique, Zimbabwe, and Western Australia.
- Establishment of a Hong Kong Joint Venture Company and ongoing efforts to set up a UAE Subsidiary Company.
- Completion of Phase 2 Ground Exploration at the Shawa Carbonatite Project in Zimbabwe with highly anomalous pXRF results.
- Encouraging pXRF anomalism from first pass soil sampling at the Lake Johnston and Forrestania lithium projects in Western Australia.
- Raised $800,000 through a capital placement to advance the binding HMS Joint Venture.
- Grant of Olinga Exploration Licence 11005L in Mozambique over potential Uranium and Rare Earth Element mineralised areas.
- Development of significant new local infrastructure within or adjacent to MRG’s Corridor HMS tenements in Mozambique.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Haranga Resources Limited (HAR) ORDINARY FULLY PAID |
Materials |
$15 |
Sanela Prospect Shaping for New Uranium Discovery
|
30 Jul 2024 9:04AM |
$0.072 |
$0.068 |
fallen by
5.56%
|
|
HAR - Price-sensitive ASX Announcement
Full Release
Key Points
- 337 auger holes drilled at Sanela prospect.
- Significant uranium anomalism identified in 234 out of 337 auger holes.
- Potential extensions along the Sanela structure being explored.
- Recent RC drilling confirmed significant uranium mineralisation.
- Sanela has potential to be the first new discovery at Saraya project.
- Haranga plans to update Saraya Indicated and Inferred mineral resource.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Superloop Limited (SLC) ORDINARY FULLY PAID |
Communication Services |
$1,505 |
Full Year FY24 Results Release Date
|
30 Jul 2024 9:04AM |
$1.485 |
$2.940 |
risen by
97.98%
|
|
| Aeeris Ltd (AER) ORDINARY FULLY PAID |
Communication Services |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2024 9:04AM |
$0.092 |
$0.070 |
fallen by
23.91%
|
|
AER - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic partnership with Tomorrow.io driving multiple customer acquisitions
- Major contract renewals for both EWN and Climatics subsidiaries
- Revenue for the period was $716,824 (unaudited)
- Customer receipts for the quarter were $677,508 (unaudited)
- Cash and cash equivalents at the end of the quarter were $1,904,545
- Annual Recurring Revenue (ARR) increased by 11.9%
- Customer retention rate exceeded 98%
- Positive feedback from the first internal audit towards ISO27001 certification
- New customer acquisitions and major contract renewals with insurers and environmental consulting firms
- Expansion of Climatics services into New Zealand
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Zelira Therapeutics Limited (ZLD) ORDINARY FULLY PAID |
Health Care |
$5 |
June 2024 Quarterly Activities Report
|
30 Jul 2024 9:04AM |
$0.630 |
$0.450 |
fallen by
28.57%
|
|
ZLD - Price-sensitive ASX Announcement
Full Release
Key Points
- Receipt of third tranche of HOPE® SPV funding totalling US$681k
- Receipt of A$919k R&D Tax Incentive
- Successful pre-IND meeting with the FDA for HOPE® 1
- Securing of leading patents for HOPE® 1 and HOPE® 2 formulations in Australia and US
- Completion of transformation of Zenivol® to capsule formulation expected by late 2024 or early 2025
- Zelira received US$1.4 million unsecured loan facility
- Operational expenses and financial snapshot for Q4 FY2024 detailed
- Continued focus on clinical validation strategy and product development
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| The Calmer Co International Limited (CCO) ORDINARY FULLY PAID |
Consumer Staple |
$9 |
Coles Expands Ranging by 40%
|
30 Jul 2024 9:03AM |
$0.008 |
$0.003 |
fallen by
62.50%
|
|
CCO - Price-sensitive ASX Announcement
Full Release
Key Points
- Coles Australia will expand the ranging of The Calmer Co’s products by 40%
- The most profitable product, Instant Kava 150g, will now be ranged in 632 Coles locations
- Taki Mai Kava Shots will now be ranged in 752 Coles locations
- Fiji Kava Instant Kava 50g will increase ranging to 799 locations
- The company will run an Out-of-Home advertising campaign in New South Wales
- The campaign aims to increase awareness of the products available in Coles and highlight in-store locations and weekly specials
- The Calmer Co. products are sold nationally in Coles except for certain regions
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Siren Gold Limited (SNG) ORDINARY FULLY PAID |
Materials |
$10 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2024 9:03AM |
$0.067 |
$0.047 |
fallen by
29.85%
|
|
SNG - Price-sensitive ASX Announcement
Full Release
Key Points
- Siren Gold Limited reported cash flows for the quarter ending June 30, 2024.
- The company had significant exploration and evaluation activities, particularly at Auld Creek, Lyell, Cumberland, and Sams Creek.
- A definitive agreement was entered with RUA Gold Inc. for the sale of the Reefton Project.
- Siren's cash balance at the end of the quarter was $1,343k.
- The company's exploration activities identified significant gold and antimony mineralization.
- Future exploration plans include extending soil surveys and completing a scoping study at Sams Creek.
- Siren expects further funding from the sale of Reefton Resources to support ongoing operations.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| BlinkLab Limited (BB1) ORDINARY FULLY PAID |
Health Care |
$44 |
BlinkLab Partners with Mental Care Group in Europe
|
30 Jul 2024 9:03AM |
$0.260 |
$0.505 |
risen by
94.23%
|
|
BB1 - Price-sensitive ASX Announcement
Full Release
Key Points
- Strategic partnership with Europe's fifth largest outpatient mental health care provider, Mental Care Group.
- Successful pilot study validated BlinkLab’s technology in a clinical setting.
- Initial study showed heightened sensory sensitivity in children with ADHD measured via the BlinkLab app.
- Partnership to accelerate BlinkLab’s path to European and US regulatory approval for ADHD.
- Collaboration aims to scale technology for broader patient groups and additional diagnoses.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Toubani Resources Inc (TRE) ORDINARY FULLY PAID |
Materials |
$75 |
Quarterly Activities/Appendix 5B Cash Flow Report
|
30 Jul 2024 9:03AM |
$0.185 |
$0.290 |
risen by
56.76%
|
|
TRE - Price-sensitive ASX Announcement
Full Release
Key Points
- Upgraded Kobada Mineral Resource Estimate to 2.2 million ounces of gold
- Substantial increase in Indicated resources category to 2.0 million ounces
- Definitive Feasibility Study update on track for completion later in 2024
- Detailed financial operations including cash flows from financing activities
- Community development projects including a new vegetable garden for Kobada village
- Adoption of Mali's 2023 Mining Code Implementation Decree for regulatory stability
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
| Argent Biopharma Limited (RGT) ORDINARY FULLY PAID |
Health Care |
$5 |
Quarterly Activities/Appendix 4C Cash Flow Report
|
30 Jul 2024 9:02AM |
$0.285 |
$0.075 |
fallen by
73.68%
|
|
RGT - Price-sensitive ASX Announcement
Full Release
Key Points
- Argent BioPharma's shares started trading on the OTCQB Venture Market under the ticker RTGLF.
- Igor Bluvstein was appointed as the Chief Financial Officer.
- Revenue for the June 2024 quarter was in line with the quarterly average sales.
- Shore Capital was appointed as the UK Corporate Broker.
- Argent BioPharma raised US$500,000 through the issue of new ordinary shares and warrants.
- The company raised an additional US$2,000,000 through a private placement after the end of the quarter.
- Proceeds from the placements will support the continuation of the drug development pipeline.
- Total cash on hand at the end of June 2024 was A$703k.
- Cash outflows included A$14k associated with cost of sales and A$426k for R&D.
- Payments to related parties during the quarter totaled A$140k.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should
refer to the full announcement here for further information.
Goals & planningInvesting goal hubsSaving to build wealth
Saving for happy retirement 
Call 1300 880 160
Start a chat
Schedule a call
